Datopotamab deruxtecan is an ADC made up of a highly effective topoisomerase I inhibitor payload chemically attached to a humanized anti-Trop-2 IgG1 monoclonal antibody using a tetra peptide-based cleavable linker that is stable and tumor-selective [88]. The gene discussed is TACSTD2; the disease is neoplasm.